← Back to writing
    longevityhealth-tech

    Longevity Clinics Need to Focus on Follow Up

    On Friday I was at the Codes of Culture Summit in London. Most of the day was about luxury brands and fandom. The longevity session was a fireside chat with an investor in longevity biotech. The investor's view was that most longevity clinics are not sustainable, because patients do not come back. They leave with a full body scan and a PDF. He no longer believes in the brick and mortar longevity clinic and sees it moving into the home, with sensors in the apartment, a telehealth doctor, and someone from the lab coming once a month to take blood. To him that is also the future of luxury real estate. I have built two clinics and I agree with him on the problem. I think a clinic can still work if it is designed around the follow up instead of the first appointment. Near the end the conversation turned to GLP-1s. The view from the stage was that it is still early for them, and that some people in the field think they could have real longevity benefits. I spend most of my time on GLP-1s now, and they have the same follow up problem. In the home version, who notices when the dose needs to change?